SIGA TechnologiesNASDAQ: SIGA

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SAN FRANCISCO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical company SIGA Technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product, TPOXX®, to treat Mpox.

NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclonal antibodies (mAbs) which could be used as potential treatments for a broad range of orthopoxviruses, including smallpox and mpox. Under the agreement, SIGA has exercised its option to license the exclusive rights to develop, manufacture, and commercialize these mAbs globally.

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.